Literature DB >> 6375804

Metronidazole in the treatment of non-specific vaginitis (NSV).

F Jerve, T B Berdal, P Bohman, C C Smith, O K Evjen, H Gjønnaess, M Gaasemyr, L Hausken, K Hesla, E Hoftvedt.   

Abstract

In a large multicentre study of 429 patients with the usual signs and symptoms of non-specific vaginitis (NSV), we studied the effect of different doses of metronidazole. The patients were divided into five treatment groups as follows: group A was given 400 mg metronidazole three times daily for seven days, group B 2000 mg as a single dose, group C 2000 mg on days 1 and 2, group D 2000 mg on days 1 and 3, and group E was given 1200 mg metronidazole once daily for five days. At follow up examination four weeks from the start of treatment, patients in groups D and E showed the best clinical results with cure rates of 94.0% and 93.6% respectively. In addition the rate of reisolation of Gardnerella vaginalis was lowest in group D. We therefore recommend metronidazole 2000 mg on days 1 and 3 as routine treatment for non-specific or vaginitis associated with gardnerella.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6375804      PMCID: PMC1046293          DOI: 10.1136/sti.60.3.171

Source DB:  PubMed          Journal:  Br J Vener Dis        ISSN: 0007-134X


  9 in total

1.  Haemophilus vaginalis vaginitis: a newly defined specific infection previously classified non-specific vaginitis.

Authors:  H L GARDNER; C D DUKES
Journal:  Am J Obstet Gynecol       Date:  1955-05       Impact factor: 8.661

2.  Nonspecific vaginitis: role of Haemophilus vaginalis and treatment with metronidazole.

Authors:  T A Pheifer; P S Forsyth; M A Durfee; H M Pollock; K K Holmes
Journal:  N Engl J Med       Date:  1978-06-29       Impact factor: 91.245

3.  Rapid presumptive identification of Gardnerella vaginalis (Haemophilus vaginalis) from human blood agar media.

Authors:  C E Shaw; M E Forsyth; W R Bowie; W A Black
Journal:  J Clin Microbiol       Date:  1981-07       Impact factor: 5.948

4.  The role of Gardnerella vaginalis in nonspecific vaginitis.

Authors:  L A Vontver; D A Eschenbach
Journal:  Clin Obstet Gynecol       Date:  1981-06       Impact factor: 2.190

5.  Anaerobic bacteria in nonspecific vaginitis.

Authors:  C A Spiegel; R Amsel; D Eschenbach; F Schoenknecht; K K Holmes
Journal:  N Engl J Med       Date:  1980-09-11       Impact factor: 91.245

Review 6.  Drug therapy: metronidazole.

Authors:  J Koch-Weser; P Goldman
Journal:  N Engl J Med       Date:  1980-11-20       Impact factor: 91.245

7.  Treatment of Hemophilus vaginalis vaginitis.

Authors:  M Malouf; M Fortier; G Morin; J L Dube
Journal:  Obstet Gynecol       Date:  1981-06       Impact factor: 7.661

8.  Pharmacokinetics of metronidazole and its principal metabolites and their activity against Gardnerella vaginalis.

Authors:  C S Easmon; C A Ison; C M Kaye; R M Timewell; S G Dawson
Journal:  Br J Vener Dis       Date:  1982-08

9.  Corynebacterium vaginale and vaginitis: a controlled trial of treatment.

Authors:  M J Balsdon; G E Taylor; L Pead; R Maskell
Journal:  Lancet       Date:  1980-03-08       Impact factor: 79.321

  9 in total
  7 in total

Review 1.  [Inflammations of the lower genital tract].

Authors:  N Pavić
Journal:  Arch Gynecol Obstet       Date:  1987       Impact factor: 2.344

2.  Pharmacokinetics of metronidazole in pregnant patients with bacterial vaginosis.

Authors:  Xin Wang; Tatiana N Nanovskaya; Ying Zhan; Susan M Abdel-Rahman; Marlo Jasek; Gary D V Hankins; Mahmoud S Ahmed
Journal:  J Matern Fetal Neonatal Med       Date:  2010-07-07

Review 3.  Antibiotic treatment for the sexual partners of women with bacterial vaginosis.

Authors:  Jairo Amaya-Guio; David Andres Viveros-Carreño; Eloisa Mercedes Sierra-Barrios; Mercy Yolima Martinez-Velasquez; Carlos F Grillo-Ardila
Journal:  Cochrane Database Syst Rev       Date:  2016-10-01

Review 4.  Vaginitis: current microbiologic and clinical concepts.

Authors:  L V Hill; J A Embil
Journal:  CMAJ       Date:  1986-02-15       Impact factor: 8.262

Review 5.  Evaluation and management of vaginitis.

Authors:  P L Carr; D Felsenstein; R H Friedman
Journal:  J Gen Intern Med       Date:  1998-05       Impact factor: 5.128

6.  Improvement of vaginal health for Kenyan women at risk for acquisition of human immunodeficiency virus type 1: results of a randomized trial.

Authors:  R Scott McClelland; Barbra A Richardson; Wisal M Hassan; Vrasha Chohan; Ludo Lavreys; Kishorchandra Mandaliya; James Kiarie; Walter Jaoko; Jeckoniah O Ndinya-Achola; Jared M Baeten; Ann E Kurth; King K Holmes
Journal:  J Infect Dis       Date:  2008-05-15       Impact factor: 5.226

7.  Should male consorts of women with bacterial vaginosis be treated?

Authors:  H Moi; R Erkkola; F Jerve; G Nelleman; B Bymose; K Alaksen; E Tornqvist
Journal:  Genitourin Med       Date:  1989-08
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.